BIOA-B Stock Analysis: BioArctic (publ) | ST
Biotechnology | ST, Sweden | Market Cap: 28.487m SEK | 12M Return: 8.3% | SE0010323311 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 39.2M
Qual. Beats: 0
Rev. Trend: 61.5%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 9 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
BioArctic AB (publ) is a Swedish biotechnology company that develops biological drugs, particularly antibody-based therapies, for central nervous system (CNS) disorders. Founded in 2000 and headquartered in Stockholm, the company targets neurodegenerative diseases with high unmet medical needs, including Alzheimers disease, Parkinsons disease, and ALS.
Its lead product, Lecanemab, is offered for intravenous treatment, with a subcutaneous formulation currently in registration. The pipeline also includes lecanemab in Phase 3 trials for presymptomatic Alzheimers treatment, Exidavnemab in Phase 2, and several preclinical and research-stage candidates such as BAN2803, ND3014, BAN2802, ND-BT8825, HD-BT4801, GD-BT6822, ND-BT3814, and PD-BT2238.
Operating as a clinical-stage biotech, BioArctic works within a sector defined by long R&D timelines, capital-intensive development, and a typical reliance on partnerships or licensing agreements with larger pharmaceutical companies for late-stage trials and commercialization.
- Lecanemab royalties from Eisai drive revenue growth
- Subcutaneous Lecanemab approval expands Alzheimers market access
- Eli Lillys Kisunla competition pressures Lecanemab share
| Net Income: 105.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA -36.47 > 1.0 |
| NWC/Revenue: 200.1% < 20% (prev 106.3%; Δ 93.89% < -1%) |
| CFO/TA 0.09 > 3% & CFO 244.0m > Net Income 105.5m |
| Net Debt (-1.90b) to EBITDA (224.3m): -8.47 < 3 |
| Current Ratio: 3.99 > 1.5 & < 3 |
| Outstanding Shares: last quarter (88.7m) vs 12m ago 0.22% < -2% |
| Gross Margin: 93.17% > 18% (prev 97.21%; Δ -4.05% > 0.5%) |
| Asset Turnover: 38.94% > 50% (prev 79.82%; Δ -40.88% > 0%) |
| Interest Coverage Ratio: 23.21 > 6 (EBIT TTM 211.5m / Interest Expense TTM 9.11m) |
| A: 0.71 (Total Current Assets 2.68b - Total Current Liabilities 670.6m) / Total Assets 2.82b |
| B: 0.48 (Retained Earnings 1.35b / Total Assets 2.82b) |
| C: 0.08 (EBIT TTM 211.5m / Avg Total Assets 2.57b) |
| D: 2.51 (Book Value of Equity 2.02b / Total Liabilities 802.8m) |
| Altman-Z'' = 9.42 = AAA |
As of September 27, 2026, the stock is trading at SEK 313.20 with a total of 134,265 shares traded. Over the past week, the price has changed by -2.43%, over one month by -9.22%, over three months by +1.10% and over the past year by +8.34%.
Current recommended Stop Loss: 301.60 (which is 3.7% or 1.2 ATR below the current price).
BioArctic (publ) has no consensus analysts rating.
P/E Trailing = 274.359
P/E Forward = 20.7469
P/S = 28.4163
P/B = 14.2871
Revenue TTM = 1.00b SEK
EBIT TTM = 211.5m SEK
EBITDA TTM = 224.3m SEK
Long Term Debt = 28.3m SEK (from longTermDebtTotal, last fiscal year)
Short Term Debt = 17.5m SEK (from shortTermDebt, last quarter)
Debt = 90.6m SEK (from shortLongTermDebtTotal, last quarter) (leases 90.6m already included)
Net Debt = -1.90b SEK (calculated: Debt 90.6m - CCE 1.99b)
Enterprise Value = 26.6b SEK (28.5b + Debt 90.6m - CCE 1.99b)
Interest Coverage Ratio = 23.21 (Ebit TTM 211.5m / Interest Expense TTM 9.11m)
EV/FCF = 109.0x (Enterprise Value 26.6b / FCF TTM 244.0m)
FCF Yield = 0.92% (FCF TTM 244.0m / Enterprise Value 26.6b)
FCF Margin = 24.34% (FCF TTM 244.0m / Revenue TTM 1.00b)
Net Margin = 10.53% (Net Income TTM 105.5m / Revenue TTM 1.00b)
Gross Margin = 93.17% ((Revenue TTM 1.00b - Cost of Revenue TTM 68.5m) / Revenue TTM)
Gross Margin QoQ = 91.24% (prev none%)
Tobins Q-Ratio = 9.43 (Enterprise Value 26.6b / Total Assets 2.82b)
Interest Expense / Debt = 10.05% (Interest Expense 9.11m / Debt 90.6m)
Taxrate = 18.58% (233.3m / 1.26b)
NOPAT = 172.2m (EBIT 211.5m * (1 - 18.58%))
Current Ratio = 3.99 (Total Current Assets 2.68b / Total Current Liabilities 670.6m)
Debt / Equity = 0.04 (Debt 90.6m / totalStockholderEquity, last quarter 2.02b)
Debt / EBITDA = -8.47 (Net Debt -1.90b / EBITDA 224.3m)
Debt / FCF = -7.79 (Net Debt -1.90b / FCF TTM 244.0m)
Total Stockholder Equity = 2.04b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.10% (Net Income 105.5m / Total Assets 2.82b)
RoE = 5.18% (Net Income TTM 105.5m / Total Stockholder Equity 2.04b)
RoCE = 10.24% (EBIT 211.5m / Capital Employed (Equity 2.04b + L.T.Debt 28.3m))
RoIC = 8.14% (NOPAT 172.2m / Invested Capital 2.12b)
WACC = 7.52% (E(28.5b)/V(28.6b) * Re(7.52%) + D(90.6m)/V(28.6b) * Rd(10.05%) * (1-Tc(0.19)))
Discount Rate = 7.52% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 70.69 | Cagr: 0.20%
[DCF] Terminal Value 73.10% ; FCFF base≈566.9m ; Y1≈497.1m ; Y5≈401.7m
[DCF] Fair Price = 112.3 (EV 6.45b - Net Debt -1.90b = Equity 8.35b / Shares 74.3m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.20 | # QB: 0
Revenue Correlation: 61.54 | Revenue CAGR: 84.75% | SUE: 0.36 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.24 | Chg30d=+366.67% | Revisions=-25% | Analysts=1
EPS current Year (2026-12-31): EPS=5.71 | Chg30d=+80.57% | Revisions=+40% | GrowthEPS=-50.4% | GrowthRev=-22.7%
EPS next Year (2027-12-31): EPS=6.91 | Chg30d=-8.84% | Revisions=+0% | GrowthEPS=+20.9% | GrowthRev=+26.1%
[Analyst] Revisions Ratio: +12% (up=3, down=2)